鲁克索利提尼布通过抑制NF-κB/MAPK信号通路来减弱微质炎症反应
Jingli Min1, Hongmei Zheng1, Heye Xia1
1Affiliated Yongkang First People's Hospital and School of Pharmacy, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
卢克索利提尼布是一种简氏激酶 (JAK) 抑制剂,通过抑制关键炎症标志物和通路,有效降低神经炎症. 这项研究表明它作为微质介导的神经疾病的治疗剂的潜力.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经炎症与各种神经疾病有关.
- 抑制神经炎症是一种有前途的治疗策略.
- 卢克索利提尼布是一种Janus激酶 (JAK) 抑制剂,已获得FDA批准用于炎症性疾病.
研究的目的:
- 研究ruxolitinib在缓解神经炎症方面的潜力.
- 阐明ruxolitinib对神经炎症通路的影响背后的机制.
主要方法:
- 使用脂聚糖 (LPS) 诱导的神经炎症细胞模型.
- 在小鼠中,Ruxolitinib 通过脑内静脉管内给药.
- 评估了炎症性细胞因子 (IL-1β,IL-6,TNF-α) 的表达.
- 检查了微质细胞和星球细胞的激活.
- 研究了基因激活蛋白激酶/核因子-κ B (MAPK/NF-κB) 信号通路.
主要成果:
- 鲁克索利提尼布在体外降低了IL-1β,IL-6和TNF-α水平.
- 鲁克索利提尼布抑制了MAPK/NF-κB信号通路.
- 卢克索利提尼布在体内降低了LPS刺激的微质细胞和天体细胞激活.
- 鲁克索利提尼布在体内减弱了促炎性细胞因子的表达.
结论:
- 鲁克索利提尼布在体外和体内都能有效减轻神经炎症反应.
- 抗神经炎症作用部分通过抑制MAPK/NF-κB通路而得到介导.
- 鲁克索利提尼布显示出作为微质介导的神经炎症治疗药物的潜力.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
相关概念视频
The JAK-STAT Signaling Pathway
MAPK Signaling Cascades
TGF - β Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
